◀ Back to ABL1

ABL1 — KIT

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Hprd Interaction: KIT — ABL1 (in vivo) Sette et al., EMBO J 2002*
• IRef Hprd Interaction: KIT — ABL1 (in vitro) Sette et al., EMBO J 2002*

Text-mined interactions from Literome

Makishima et al., Leukemia 2012 (Leukemia, Myeloid, Acute) : GDM-1, but not the other cell lines, was highly sensitive to growth inhibition by dasatinib ( dual SFK and RTK inhibitor, LD50 50 nM ) ; there was less or no selective inhibition of GDM-1 growth by sunitinib ( RTK inhibitor ), imatinib ( ABL , KIT inhibitor ), or PP2 ( SFK inhibitor )
Hallek et al., Br J Haematol 1996 (Leukemia, Myelogenous, Chronic, BCR-ABL Positive) : Immune complex kinase assays showed that the kinase activity of p145c-kit was several-fold higher in MO7p210 and 32Dp210kit cells than in MO7, 32Dkit and 32Dp210 ( Arg271 ) kit cells, suggesting that Abl kinase activity was necessary to activate p145c-kit